



Burkhard Göke

Kontakt

Burkhard Göke

Publikationen (61)

Schnitzler F, Grüner N, Rust C, Guba M, Denk G, Zchoval R, Göke B, Tillack C, Beigel F, Olszak T, Angelberger M, Wolf C, Karbalai N, Habicht A, Fischereider M, Schönemarck U, Stallhofer J, Friedrich M, Brand S. Solid Organ Transplantation in Patients with Inflammatory Bowel Diseases (IBD): Analysis of Transplantation Outcome and IBD Activity in a Large Single Center Cohort. *PLoS one* 2015; 10:e0135807.

Schnitzler F, Lohse P, Glas J, Göke B, Beigel F, Tillack C, Olszak T, Diegelmann J, Angelberger M, Stallhofer J, Wolf C, Friedrich M, Brand S. The NOD2 Single Nucleotide Polymorphism rs72796353 (IVS4+10 A>C) Is a Predictor for Perianal Fistulas in Patients with Crohn's Disease in the Absence of Other NOD2 Mutations. *PLoS one* 2015; 10:e0116044.

Schnitzler F, Lohse P, Glas J, Göke B, Stallhofer J, Tillack C, Beigel F, Olszak T, Diegelmann J, Angelberger M, Wolf C, Friedrich M, Brand S. The NOD2 p.Leu1007fsX1008 mutation (rs2066847) is a stronger predictor of the clinical course of Crohn's disease than the FOXO3A intron variant rs12212067. *PLoS one* 2014; 9:e108503.

Beigel F, Brand S, Göke B, Rust C, Breitenreicher S, Maul J, Lammert F, Howaldt S, Teich N, Ochsenkühn T. Colesevelam for the treatment of bile acid malabsorption-associated diarrhea in patients with Crohn's disease: a randomized, double-blind, placebo-controlled study. *J Crohns Colitis* 2014; 8:1471-9.

Beigel F, Deml M, Schnitzler F, Breitenreicher S, Göke B, Ochsenkühn T, Brand S. Rate and predictors of mucosal healing in patients with inflammatory bowel disease treated with anti-TNF-alpha antibodies. *PLoS one* 2014; 9:e99293.

Beigel F, Brand S, Seiderer J, Göke B, Laubender R, Van Steen K, John J, Breitenreicher S, Tillack C, Schnitzler F, Steinborn A, Ochsenkühn T. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies. *Pharmacoepidemiol Drug Saf* 2014; 23:735-44.

Beigel F, Friedrich M, Probst C, Sotlar K, Göke B, Diegelmann J, Brand S. Oncostatin M mediates STAT3-dependent intestinal epithelial restitution via increased cell proliferation, decreased apoptosis and upregulation of SERPIN family members. *PLoS one* 2014; 9:e93498.

Diegelmann J, Glas J, Franke A, Göke B, Bedynek A, Olszak T, Zimmermann E, Le Bras E, Czamara D, Brand S. Intestinal DMBT1 expression is modulated by Crohn's disease-associated IL23R variants and by a DMBT1 variant which influences binding of the transcription factors CREB1 and ATF-2. *PLoS one* 2013; 8:e77773.

Steib C, Gmelin L, Pfeiler S, Schewe J, Brand S, Göke B, Gerbes A. Functional relevance of the cannabinoid receptor 2 - heme oxygenase pathway: a novel target for the attenuation of portal hypertension. *Life Sci* 2013; 93:543-51.

Glas J, Czamara D, Diegelmann J, Göke B, Friedrich M, Steib C, Beigel F, Wetzke M, Tsekere E, Olszak T, Fries C, Stallhofer J, Bues S, Seiderer J, Brand S. IRGM variants and susceptibility to inflammatory bowel disease in the German population. *PLoS one* 2013; 8:e54338.

Zitzmann K, Vlotides G, Brand S, Lahm H, Spöttl G, Göke B, Auernhammer C. Perifosine-mediated Akt inhibition in neuroendocrine tumor cells: role of specific Akt isoforms. *Endocr Relat Cancer* 2012; 19:423-34.

Glas J, Czamara D, Diegelmann J, Ochsenkühn T, Göke B, Wetzke M, Steib C, Stallhofer J, Beigel F, Friedrich M, Tillack C, Fries C, Olszak T, Wagner J, Seiderer J, Brand S. Analysis of IL12B gene variants in inflammatory bowel disease. *PLoS one* 2012; 7:e34349.

Glas J, Czamara D, Diegelmann J, Karbalai N, Ochsenkühn T, Göke B, Steib C, Friedrich M, Stallhofer J, Tillack C, Beigel F, Wetzke M, Olszak T, Seiderer J, Wagner J, Brand S. PTPN2 gene variants are associated with susceptibility to both Crohn's disease and ulcerative colitis supporting a common genetic disease background. *PloS one* 2012; 7:e33682.

Beigel F, Ochsenkühn T, Seiderer J, Göke B, Weidinger M, Breitenreicher S, Schnitzler F, Tillack C, Laubender R, Löhr B, Brand S. Iron status and analysis of efficacy and safety of ferric carboxymaltose treatment in patients with inflammatory bowel disease. *Digestion* 2011; 85:47-54.

Diegelmann J, Olszak T, Göke B, Blumberg R, Brand S. A novel role for interleukin-27 (IL-27) as mediator of intestinal epithelial barrier protection mediated via differential signal transducer and activator of transcription (STAT) protein signaling and induction of antibacterial and anti-inflammatory proteins. *J Biol Chem* 2011; 287:286-98.

Glas J, Czamara D, Diegelmann J, Müller-Myhsok B, Lohse P, Wolf C, Ochsenkühn T, Göke B, Lass U, Olszak T, Beigel F, Weidinger M, Pfennig S, Tillack C, Fries C, Seiderer J, Brand S. CEACAM6 gene variants in inflammatory bowel disease. *PloS one* 2011; 6:e19319.

Zitzmann K, de Toni E, von Rüden J, Brand S, Göke B, Laubender R, Auernhammer C. The novel Raf inhibitor Raf265 decreases Bcl-2 levels and confers TRAIL-sensitivity to neuroendocrine tumour cells. *Endocr Relat Cancer* 2011; 18:277-85.

Stallhofer J, Denk G, Glas J, Laubender R, Göke B, Rust C, Brand S, Pusi T. Analysis of IL2/IL21 gene variants in cholestatic liver diseases reveals an association with primary sclerosing cholangitis. *Digestion* 2011; 84:29-35.

Beigel F, Schnitzler F, Paul Laubender R, Pfennig S, Weidinger M, Göke B, Seiderer J, Ochsenkühn T, Brand S. Formation of antinuclear and double-strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF- α antibody-treated patients with inflammatory bowel disease. *Inflamm Bowel Dis* 2011; 17:91-8.

Glas J, Czamara D, Diegelmann J, Lohse P, Ochsenkühn T, Göke B, Müller-Myhsok B, Weidinger M, Laubender R, Olszak T, Jürgens M, Beigel F, Pfennig S, Tillack C, Seiderer J, Brand S. The NOD2 single nucleotide polymorphisms rs2066843 and rs2076756 are novel and common Crohn's disease susceptibility gene variants. *PloS one* 2010; 5:e14466.

Diegelmann J, Beigel F, Zitzmann K, Kaul A, Göke B, Auernhammer C, Bartenschlager R, Diepolder H, Brand S. Comparative analysis of the lambda-interferons IL-28A and IL-29 regarding their transcriptome and their antiviral properties against hepatitis C virus. *PloS one* 2010; 5:e15200.

Glas J, Czamara D, Diegelmann J, Müller-Myhsok B, Folwaczny M, Ochsenkühn T, Göke B, Weidinger M, Olszak T, Beigel F, Wetzke M, Pfennig S, Tengler B, Fischer D, Seiderer J, Brand S. Pregnane X receptor (PXR/NR112) gene haplotypes modulate susceptibility to inflammatory bowel disease. *Inflamm Bowel Dis* 2010; 17:1917-24.

Diegelmann J, Seiderer J, Niess J, Haller D, Göke B, Reinecker H, Brand S. Expression and regulation of the chemokine CXCL16 in Crohn's disease and models of intestinal inflammation. *Inflamm Bowel Dis* 2010; 16:1871-81.

Jürgens M, Ochsenkühn T, Göke B, Tillack C, Beigel F, Hasbargen U, Hübener C, Filik L, Brand S, Seiderer J. Safety of adalimumab in Crohn's disease during pregnancy: case report and review of the literature. *Inflamm Bowel Dis* 2010; 16:1634-6.

Glas J, Roeske D, Diegelmann J, Müller-Myhsok B, Ochsenkühn T, Göke B, Paschos E, Wetzke M, Pfennig S, Markus C, Seiderer J, Brand S. Role of PPARG gene variants in inflammatory bowel disease. *Inflamm Bowel Dis* 2010; 17:1057-8.

Glas J, Roeske D, Müller-Myhsok B, Diegelmann J, Ochsenkühn T, Göke B, Folwaczny M, Lohse P, Epplen J, Klein W, Pfennig S, Weidinger M, Beigel F, Fries C, Nagy M, Seiderer J, Brand S. Evidence for STAT4 as a common autoimmune gene: rs7574865 is associated with colonic Crohn's disease and early disease onset. *PloS one* 2010; 5:e10373.

Jürgens M, Herrmann K, Lohse P, Göke B, Kreis M, Schnitzler F, Weidinger M, Beigel F, Tillack C, Pfennig S, Wagner J, Wetzke M, Glas J, Seiderer J, Laubender R, Brand S, Ochsenkühn T. The presence of fistulas and NOD2 homozygosity strongly predict intestinal stenosis in Crohn's disease independent of the IL23R genotype. *J Gastroenterol* 2010; 45:721-31.

Zitzmann K, Rüden J, Brand S, Göke B, Lichtl J, Spöttl G, Auernhammer C. Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease. *Cancer Lett* 2010; 295:100-9.

Jürgens M, Ochsenkühn T, Glas J, Göke B, Lohse P, Tillack C, Schnitzler F, Stallhofer J, Pfennig S, Beigel F, Wetzke M, Wagner J, Seiderer J, Weidinger M, Hartl F, Laubender R, Brand S. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. *Am J Gastroenterol* 2010; 105:1811-9.

Storr M, Emmerdinger D, Diegelmann J, Pfennig S, Ochsenkühn T, Göke B, Lohse P, Brand S. The cannabinoid 1 receptor (CNR1) 1359 G/A polymorphism modulates susceptibility to ulcerative colitis and the phenotype in Crohn's disease. *PloS one* 2010; 5:e9453.

Beigel F, Jürgens M, Filik L, Bader L, Lück C, Göke B, Ochsenkühn T, Brand S, Seiderer J. Severe Legionella pneumophila pneumonia following infliximab therapy in a patient with Crohn's disease. *Inflamm Bowel Dis* 2009; 15:1240-4.

Beigel F, Jürgens M, Tillack C, Subklewe M, Mayr D, Göke B, Brand S, Ochsenkühn T. Hepatosplenic T-cell lymphoma in a patient with Crohn's disease. *Nat Rev Gastroenterol Hepatol* 2009; 6:433-6.

Török H, Müller-Myhsok B, Folwaczny C, Göke B, Folwaczny M, Ochsenkühn T, Lohse P, Klein W, Wetzke M, Teshome M, Tonenchi L, Endres I, Glas J, Brand S. Epistasis between Toll-like receptor-9 polymorphisms and variants in NOD2 and IL23R modulates susceptibility to Crohn's disease. *Am J Gastroenterol* 2009; 104:1723-33.

Glas J, Müller-Myhsok B, Ochsenkühn T, Göke B, Lohse P, Folwaczny M, Koletzko S, Lacher M, Schiemann U, Griga T, Epplen J, Klein W, Pfennig S, Wetzke M, Ripke S, Stallhofer J, Brand S. Novel genetic risk markers for ulcerative colitis in the IL2/IL21 region are in epistasis with IL23R and suggest a common genetic background for ulcerative colitis and celiac disease. *Am J Gastroenterol* 2009; 104:1737-44.

Glas J, Klein W, Epplen J, Schiemann U, Mussack T, Lohse P, Göke B, Ochsenkühn T, Folwaczny M, Müller-Myhsok B, Griga T, Jürgens M, Stallhofer J, Seiderer J, Pasciuto G, Tillack C, Diegelmann J, Pfennig S, Konrad A, Schmechel S, Wetzke M, Török H, Brand S. rs224136 on chromosome 10q21.1 and variants in PHOX2B, NCF4, and FAM92B are not major genetic risk factors for susceptibility to Crohn's disease in the German population. *Am J Gastroenterol* 2009; 104:665-72.

Tillack C, Seiderer J, Brand S, Göke B, Reiser M, Schaefer C, Diepolder H, Ochsenkühn T, Herrmann K. Correlation of magnetic resonance enteroclysis (MRE) and wireless capsule endoscopy (CE) in the diagnosis of small bowel lesions in Crohn's disease. *Inflamm Bowel Dis* 2008; 14:1219-28.

Storr M, Patel K, Brand S, Göke B, Lutz B, Buckley N, Massa F, Sibaev A, Yüce B, Zhang H, Emmerdinger D, Keenan C, Sharkey K. Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors. *J Mol Med* 2008; 86:925-36.

Pusl T, Wild N, Vennegeerts T, Wimmer R, Göke B, Brand S, Rust C. Free fatty acids sensitize hepatocytes to bile acid-induced apoptosis. *Biochem Biophys Res Commun* 2008; 371:441-5.

Seiderer J, Lohse P, Müller-Myhsok B, Ochsenkühn T, Göke B, Konrad A, Schmechel S, Jürgens M, Pfennig S, Tillack C, Stallhofer J, Glas J, Diegelmann J, Elben I, Brand S. Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn's disease and analysis of the IL17F p.His161Arg polymorphism in IBD. *Inflamm Bowel Dis* 2008; 14:437-45.

Schmechel S, Konrad A, Diegelmann J, Glas J, Wetzke M, Paschos E, Lohse P, Göke B, Brand S. Linking genetic susceptibility to Crohn's disease with Th17 cell function: IL-22 serum levels are increased in Crohn's disease and correlate with disease activity and IL23R genotype status. *Inflamm Bowel Dis* 2008; 14:204-12.

Seiderer J, Reinecker H, Lohse P, Ochsenkühn T, Göke B, Müller-Myhsok B, Jürgens M, Pfennig S, Niess J, Glas J, Tillack C, Leistner D, Dambacher J, Brand S. Genotype-phenotype analysis of the CXCL16 p.Ala181Val polymorphism in inflammatory bowel disease. *Clin Immunol* 2008; 127:49-55.

Dambacher J, Beigel F, Zitzmann K, Heeg M, Göke B, Diepolder H, Auernhammer C, Brand S. The role of interleukin-22 in hepatitis C virus infection. *Cytokine* 2008; 41:209-16.

Glas J, Klein W, Epplen J, Folwaczny C, Lohse P, Göke B, Ochsenkühn T, Mussack T, Folwaczny M, Müller-Myhsok B, Griga T, Haller D, Pfennig S, Konrad A, Schmechel S, Dambacher J, Seiderer J, Schroff F, Wetzke M, Roeske D, Török H, Tonenchi L, Brand S. The ATG16L1 gene variants rs2241879 and rs2241880 (T300A) are strongly associated with susceptibility to Crohn's disease in the German population. *Am J Gastroenterol* 2007; 103:682-91.

Glas J, Epplen J, Schiemann U, Folwaczny C, Lohse P, Göke B, Ochsenkühn T, Müller-Myhsok B, Folwaczny M, Mussack T, Klein W, Griga T, Maier K, Seiderer J, Wetzke M, Konrad A, Török H, Schmechel S, Tonenchi L, Grassl C, Dambacher J, Pfennig S, Brand S. rs1004819 is the main disease-associated IL23R variant in German Crohn's disease patients: combined analysis of IL23R, CARD15, and OCTN1/2 variants. *PLoS one* 2007; 2:e819.

Zitzmann K, Brand S, De Toni E, Baehs S, Göke B, Meinecke J, Spöttl G, Meyer H, Auernhammer C. SOCS1 silencing enhances antitumor activity of type I IFNs by regulating apoptosis in neuroendocrine tumor cells. *Cancer Res* 2007; 67:5025-32.

Dambacher J, Beigel F, Seiderer J, Haller D, Göke B, Auernhammer C, Brand S. Interleukin 31 mediates MAP kinase and STAT1/3 activation in intestinal epithelial cells and its expression is upregulated in inflammatory bowel disease. *Gut* 2007; 56:1257-65.

Zitzmann K, De Toni E, Brand S, Göke B, Meinecke J, Spöttl G, Meyer H, Auernhammer C. The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. *Neuroendocrinology* 2007; 85:54-60.

Brand S, Thasler W, Bilzer M, Diepolder H, Göke B, Storr M, Steib C, Olszak T, Prüfer T, Weiss T, Heeg M, Zitzmann K, Beigel F, Dambacher J, Auernhammer C. IL-22-mediated liver cell regeneration is abrogated by SOCS-1/3 overexpression in vitro. *Am J Physiol Gastrointest Liver Physiol* 2007; 292:G1019-28.

Dambacher J, Lohse P, Ochsenkühn T, Göke B, Diebold J, Otte J, Tillack C, Konrad A, Hofbauer K, Pfennig S, Schnitzler F, Sisic Z, Seiderer J, Staudinger T, Brand S. Macrophage migration inhibitory factor (MIF) -173G/C promoter polymorphism influences upper gastrointestinal tract involvement and disease activity in patients with Crohn's disease. *Inflamm Bowel Dis* 2007; 13:71-82.

Seiderer J, Lohse P, Göke B, Sackmann M, Tillack C, Dambacher J, Hofbauer K, Herrmann K, Pfennig S, Staudinger T, Brand S, Schnitzler F, Ochsenkühn T. Homozygosity for the CARD15 frameshift mutation 1007fs is predictive of early onset of Crohn's disease with ileal stenosis, entero-enteral fistulas, and frequent need for surgical intervention with high risk of re-stenosis. *Scand J Gastroenterol* 2006; 41:1421-32.

Seiderer J, Lohse P, Göke B, Schoenberg S, Pfennig S, Crispin A, Hatz R, Schnitzler F, Herrmann K, Brand S, Ochsenkühn T. Predictive value of the CARD15 variant 1007fs for the diagnosis of intestinal stenoses and the need for surgery in Crohn's disease in clinical practice: results of a prospective study. *Inflamm Bowel Dis* 2006; 12:1114-21.

Seiderer J, Zech C, Diebold J, Schoenberg S, Brand S, Tillack C, Göke B, Ochsenkühn T. Nodular regenerative hyperplasia: a reversible entity associated with azathioprine therapy. *Eur J Gastroenterol Hepatol* 2006; 18:553-5.

Zitzmann K, Brand S, Baehs S, Göke B, Meinecke J, Spöttl G, Meyer H, Auernhammer C. Novel interferon-lambdas induce antiproliferative effects in neuroendocrine tumor cells. *Biochem Biophys Res Commun* 2006; 344:1334-41.

Brand S, Auernhammer C, Göke B, Ochsenkühn T, Seiderer J, Herrmann K, Leclair S, Popp A, Jagla W, Marquardt A, Diepolder H, Otte J, Eichhorst S, Zitzmann K, Olszak T, Beigel F, Dambacher J. IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. *Am J Physiol Gastrointest Liver Physiol* 2006; 290:G827-38.

Brand S, Olszak T, Beigel F, Diebold J, Otte J, Eichhorst S, Göke B, Dambacher J. Cell differentiation dependent expressed CCR6 mediates ERK-1/2, SAPK/JNK, and Akt signaling resulting in proliferation and migration of colorectal cancer cells. *J Cell Biochem* 2006; 97:709-23.

Schnitzler F, Ochsenkühn T, Göke B, Tillack C, Seiderer J, Hofbauer K, Pfennig S, Staudinger T, Brand S, Lohse P. Eight novel CARD15 variants detected by DNA sequence analysis of the CARD15 gene in 111 patients with inflammatory bowel disease. *Immunogenetics* 2006; 58:99-106.

Brand S, Ochsenkühn T, Göke B, Konrad A, Tillack C, Seiderer J, Pfennig S, Staudinger T, Schnitzler F, Dambacher J, Hofbauer K, Lohse P. Increased expression of the chemokine fractalkine in Crohn's disease and association of the fractalkine receptor T280M polymorphism with a fibrostenosing disease Phenotype. *Am J Gastroenterol* 2006; 101:99-106.

Brand S, Dambacher J, Beigel F, Olszak T, Diebold J, Otte J, Göke B, Eichhorst S. CXCR4 and CXCL12 are inversely expressed in colorectal cancer cells and modulate cancer cell migration, invasion and MMP-9 activation. *Exp Cell Res* 2005; 310:117-30.

Brand S, Göke B, Auernhammer C, Adler B, Diepolder H, Diebold J, Otte J, Eichhorst S, Zitzmann K, Olszak T, Beigel F, Dambacher J. IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. *Am J Physiol Gastrointest Liver Physiol* 2005; 289:G960-8.

Brand S, Lohse P, Göke B, Crispin A, Konrad A, Tillack C, Seiderer J, Dambacher J, Hofbauer K, Pfennig S, Schnitzler F, Staudinger T, Ochsenkühn T. The role of Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms and CARD15/NOD2 mutations in the susceptibility and phenotype of Crohn's disease. *Inflamm Bowel Dis* 2005; 11:645-52.

Brand S, Diepolder H, Göke B, Eichhorst S, Vlotides G, Olszak T, Beigel F, Dambacher J, Zitzmann K, Auernhammer C. SOCS-1 inhibits expression of the antiviral proteins 2',5'-OAS and MxA induced by the novel interferon-lambdas IL-28A and IL-29. *Biochem Biophys Res Commun* 2005; 331:543-8.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch